Dr Harry Erba from Duke University reviews several key studies on myelodysplastic syndrome (MDS) presented at the 2020 American Society of Hematology annual meeting.
Dr Erba highlights a multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) vs hypomethylating therapy or best supportive care in patients age 50-75 with advanced MDS.
The study showed a 21% improvement in 3-year overall survival in patients who underwent HSCT compared with those who received hypomethylating therapy or supportive care.
Dr Erba also reports on a randomized phase 2 study evaluating the efficacy and safety of pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS.
The event-free survival of patients treated with pevonedistat and azacitidine was superior to that of patients treated with azacitidine alone. There was also a trend for improvement in overall survival.
Finally, Dr Erba discusses the results of a phase 1b study of the anti-TIM-3 monoclonal antibody sabatolimab, or MBG453, in combination with hypomethylating agents in patients with high-risk MDS.
In these patients with high-risk and very high-risk MDS, the overall response rate was 64%. The complete remission rate was only 23% and, according to Dr Erba, was similar to what might be expected with azacitidine alone.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Key Presentations on Myelodysplastic Syndrome From ASH 2020 - Medscape - Dec 28, 2020.
Comments